A PHP Error was encountered

Severity: Warning

Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests

Filename: helpers/my_audit_helper.php

Line Number: 176

Backtrace:

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url

File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3122
Function: getPubMedXML

File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global

File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword

File: /var/www/html/index.php
Line: 316
Function: require_once

Clinical multicenter evaluation of a new FXa-based Antithrombin assay. | LitMetric

Clinical multicenter evaluation of a new FXa-based Antithrombin assay.

Int J Lab Hematol

Siemens Healthcare Diagnostic Products GmbH, Marburg, Germany.

Published: October 2011

AI Article Synopsis

  • The study evaluated a new Antithrombin assay method (INNOVANCE® Antithrombin) across four analyzers to enhance thrombophilia screening.
  • The method showed excellent precision, with impressive coefficients of variation and comparable reference intervals among different analyzers.
  • The INNOVANCE Antithrombin method demonstrated strong concordance with established assays and effectively identified patients with congenital Antithrombin deficiencies, proving its reliability for clinical use.

Article Abstract

Introduction: The determination of functional Antithrombin is a central part of thrombophilia screening. In this multicenter study, a new FXa-based method (INNOVANCE® Antithrombin) was evaluated on four different analyzers.

Methods: The INNOVANCE Antithrombin method was evaluated by precision and reference interval studies and by comparing the new method with established methods through parallel measurement of samples from 249 patients and 151 apparently healthy individuals.

Results: The INNOVANCE Antithrombin assay demonstrated on all analyzers repeatability coefficients of variation (CVs) ≤ 3.2% and within-device and between-run CVs ≤ 6.9%. The reference intervals of all analyzers are comparable with 2.5th percentiles between 80% and 85% of normal. The INNOVANCE Antithrombin and the FIIa-based Berichrom® AT III (A) methods demonstrated good concordance with correlation coefficients of r = 0.908 or higher. The INNOVANCE Antithrombin method demonstrated furthermore an excellent comparability with the STA® Antithrombin III assay and an acceptable comparability with the Coamatic® LR Antithrombin assay. The patients with congenital deficiency (n = 31) were identified with all assays except for the patients carrying the P41L heparin-binding site mutation, which was only identified with the INNOVANCE Antithrombin and the STA Antithrombin III methods.

Conclusion: The INNOVANCE Antithrombin assay has high sensitivity for Antithrombin deficiencies and is reliable, precise and suitable for routine clinical use.

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1751-553X.2011.01326.xDOI Listing

Publication Analysis

Top Keywords

innovance antithrombin
24
antithrombin assay
16
antithrombin
13
antithrombin method
8
cvs ≤
8
antithrombin iii
8
innovance
6
assay
5
clinical multicenter
4
multicenter evaluation
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!